Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Collaboration › Details

SyntheticGestalt–Enamine: AI-based drug discovery, 202401– collab adding REAL database to AI-based drug discovery service of SyntheticGestalt

 

Period Period 2024-01-11
Organisations Partner, 1st SyntheticGestalt K.K.
  Group SyntheticGestalt (Group)
  Partner, 2nd Enamine Ltd. (UA)
Products Product AI-based drug discovery / AI-based drug development
  Product 2 REAL database (Enamine)
Persons Person Kos, Iaroslava (Enamine 202401 Director of Business Development)
  Person 2 Shimada, Koki (SyntheticGestalt 202401 CEO)
     

Enamine Ltd.. (1/11/24). "Press Release: Enamine and SyntheticGestalt to Collaborate on the Creation of AI-based Model to Facilitate Drug Discovery". Tokyo & Kyiv.

SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates. This model will utilize 38 billion compounds from Enamine REAL database as a dataset for pre-training.


SyntheticGestalt, a research and development company specializing in the application of AI to the life sciences domain, and Enamine, the world’s leading provider of chemical building blocks, screening compounds, and integrated drug discovery services, have announced the start of a joint effort to create a suite of AI models that will enable the generation of synthetically accessible biologically active compounds with optimized physicochemical and ADME/ Tox properties. The models will be applicable to the compound discovery initiatives of SyntheticGestalt, as well as its service for both academic users and pharmaceutical companies.

Enamine will provide access to its largest enumerated database of make-on-demand compounds, Enamine REAL database, which has 38 billion molecules in its current edition. SyntheticGestalt will add the REAL database to its Drug Discovery Service, which uses proprietary AI models to provide predictions on physicochemical and ADME/ Tox properties of compounds. For compounds with issues, the service proposes improved alternative compounds instantaneously. Enamine will synthesize the selected compounds within just 3-4 weeks and provide quality pharmacological in vitro profiling data through the in-house tests to streamline and shorten the discovery cycle.

Furthermore, SyntheticGestalt will enhance its pre-trained AI model using the data provided by Enamine. It is expected to become the largest pre-trained model in the world based on the 3D structures of the compounds, to improve the predictive accuracy of SyntheticGestalt’s machine learning models. The resulting models will be offered on a joint research basis to certain interested parties. The pre-trained AI model and its performance will be presented at NVIDIA’s annual event, NVIDIA GTC Japan AI Day, in March of 2024.

Iaroslava Kos, Director of Business Development at Enamine commented: “The promise provided by AI/ML powered computational designs in the discovery of new drugs cannot be underestimated. Finding new active compounds by synthesis of just a handful of novel compounds looks fantastic. We are pleased to enter collaboration with SyntheticGestalt bringing to the table the talent and expertise of our scientists to realize mutual goals. We look forward to joining efforts towards the long-desired therapeutics.”

Koki Shimada, CEO at SyntheticGestalt commented: “The use of machine learning in drug discovery research has long been plagued by the problem of high performance on training data but low performance in actual use. To solve this problem, it is necessary to develop pre-training models using data that will be used in real-world applications. The Enamine REAL database is the perfect match for our initiative as the most trusted and the largest make-on-demand set on the market. We believe that the ultra-large pre-trained model we are developing will enable a cosmic leap in AI drug discovery, just as the large-scale pre-training made a revolution in Large Language Models (LLMs).”


ENDS


About SyntheticGestalt

SyntheticGestalt is an artificial intelligence research and development company specialising in AI drug discovery and other life science fields. Its research and development are focused on the discovery of useful substances using its independently developed artificial intelligence technology.

The AI platform used in this research has a cloud-based, scalable structure and can make predictions on large libraries, making it possible to predict physicochemical and ADME/ Tox properties and early toxicity, as well as enzyme functions. SyntheticGestalt welcomes open innovation through joint research with public institutions and private companies. For more information visit: https://syntheticgestalt.com


About the SyntheticGestalt Drug Discovery Service

SyntheticGestalt offers a web service specifically aimed at proposing solutions to ADME/ Tox and physicochemical problems of Hit ~ Lead compounds, based on its proprietary machine learning models. The service is available for trial from the following link: https://drugdiscovery.syntheticgestalt.com/


About Enamine

Enamine is a scientifically driven integrated discovery Contract Research Organisation with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (4M in stock) and building blocks (300K in stock) with a comprehensive platform of integrated discovery services to advance and accelerate the efforts in Drug Discovery. For more information visit: https://enamine.net


About Enamine REAL Database

Enamine REAL® Database (REadily AccesibLe) is a collection of over 38 billion enumerated molecules that can be synthesized at Enamine extremely fast (3-4 weeks), with high feasibility (over 80%), and inexpensive. The REAL compounds are created by parallel chemistry through the compilation of 137,000 building blocks via 167 different synthesis protocols, underlying Enamine’s approach to design make-on-demand compounds to maximize synthesis success rate.

   
Record changed: 2024-02-24

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for SyntheticGestalt (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Top News Bayer Aignostics Collaboration 650x300px




» top